deltatrials

Chronic kidney disease Trials in Milan, Italy

Conditions / Chronic kidney disease / Milan, Italy

Chronic kidney disease has been the subject of sustained clinical investigation across multiple research sites.

36 total trials for this combination

Showing top 10 of 36 trials

Trials

NCT ID Title Status Phase
NCT05457283 A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria RECRUITING
NCT07241390 A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) RECRUITING
NCT02160145 Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease COMPLETED PHASE3
NCT02540993 Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease COMPLETED PHASE3
NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk COMPLETED
NCT07241390 A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) RECRUITING
NCT00503698 The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis TERMINATED PHASE3
NCT05196035 A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria RECRUITING
NCT05021835 ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation ACTIVE_NOT_RECRUITING PHASE3
NCT05746559 ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE ACTIVE_NOT_RECRUITING PHASE3

Related Pages